Last reviewed · How we verify

NCT05092035

Recognition of Early Pulmonary Structural Changes by Using Real-time High Fidelity Expiratory CO2 Analysis

Completed NA Last updated 21 January 2026
What this trial tests

NA trial testing single high-fidelity expiratory CO2 analysis in COPD in 40 participants. Completed in 1 March 2025.

Timeline
1 March 2020
Primary endpoint
1 March 2025
1 March 2025

Quick facts

Lead sponsorMedical University of Graz
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposediagnostic
Enrollment40
Start date1 March 2020
Primary completion1 March 2025
Estimated completion1 March 2025
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

18 and older, any sex, with COPD or ILD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study the investigators aim to detect and characterize structural airway and lung vessel changes due to COPD or ILD as assessed by real-time high fidelity expiratory CO2 analysis. The long-term goal is to detect pulmonary structural changes in a stage, when variables of currently used standard methods (e.g. pulmonary function test) are not yet altered.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing